Skip to main content

Kumar Rakhi's Form 4 filing

Roivant Sciences Ltd. (ROIV) · filed May 3, 2023

Accession no.
0001140361-23-022809
Filed
May 3, 2023
Trade date
May 1-2, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $664.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kumar RakhiCIK 0001856296Officer (Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2023Common SharesMOption exerciseAcquired+62,219$3.85+$239,543.15262,358Direct
May 1, 2023Common SharesSSaleDisposed−62,219$8.58F1−$533,839.02200,139Direct
May 2, 2023Common SharesMOption exerciseAcquired+15,517$3.85+$59,740.45215,656Direct
May 2, 2023Common SharesSSaleDisposed−15,517$8.42F1−$130,653.14200,139Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2023Common SharesMOption exerciseDisposed−62,219$0.00$0765,517Direct
May 2, 2023Common SharesMOption exerciseDisposed−15,517$0.00$0750,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)